Author: sugaradmin

Introduction and Objective: ALK7 plays a crucial role in adipose homeostasis, with genetic variants linked to obesity in human GWAS. This study examines the pharmacodynamic effects of SGB-ALK7 in cynomolgus monkeys and its therapeutic potential in an obese mouse model.Methods: SanegeneBio is developing Ligand and Enhancer Assisted Delivery (LEAD™) technology, which utilizes a receptor-mediated internalization […]

Introduction and Objective: The prevalence of type 1 diabetes (T1D) in older adults has increased over the last few decades. Many aspects of self-care may be impacted by age related changes, comorbidities, and risk of hypoglycemia. Yet, few studies have characterized the emotional burden of diabetes distress (DD) in this age group and its clinical […]

Introduction and Objective: Continuous blood glucose monitoring in mice using implantable telemetry devices is a highly sophisticated technique that measures real-time arterial blood glucose. This technique has not yet been combined with indirect calorimetry to study metabolism in obesity. By combining these techniques, this study was designed to gain a higher resolution understanding of the […]

Introduction and Objective: HRS9531, a novel once-weekly (QW) dual GLP-1/GIP receptor agonist, showed preliminary efficacy with good tolerability in T2DM participants. This phase 2 study further evaluated the efficacy and safety of HRS9531 in Chinese T2DM participants with treatment to 32 weeks which consisted of a 20-week (W) core treatment followed by a 12W extension […]

Introduction and Objective: In a large animal model of type 2 diabetes (T2D), we have shown that portal, GLP-1-dependent, glucose sensing is impaired and a low-dose dihydrotestosterone (DHT) implant inserted into the area of the portal sensor normalizes glucose metabolism acutely. We evaluated the capacity of portal DHT to achieve sustained remission of diabetes and […]

Introduction and Objective: Severe hypoglycemia can cause fatal arrhythmias, yet RH preconditioning reduces this risk (Reno et al. Diabetes 2017). We hypothesized that this protective effect in reducing arrhythmias is due to an RH preconditioning effect in improving cardiac mitochondrial function.Methods: Protocol 1: Adult male STZ-induced diabetic (D) rats were assigned to 3 days of […]

Introduction and Objective: The GLP-1: GIP receptor dual agonist Tirzepatide has demonstrated therapeutic efficacy on clinical endpoints in a recent phase 2 clinical trial in patients with metabolic-dysfunction associated steatohepatitis (MASH) and liver fibrosis. The present study aimed to evaluate therapeutic efficacy of tirzepatide on clinical endpoints and outcome in the GAN diet-induced obese (DIO) […]

Introduction and Objective: Time to treatment target is a consideration in clinical decision making. Additionally, greater magnitudes of sustained body weight (BW) reduction are shown to provide added health benefits. In SURMOUNT-5, once weekly tirzepatide (TZP) at the maximum tolerated dose (MTD) (10/15mg) resulted in significantly greater BW reduction vs semaglutide (SEMA) MTD (1.7/2.4mg) in […]

Introduction and Objective: Mouse models of obesity exhibit heterogeneity in metabolic flexibility, with diet-induced obesity (DIO) mice showing greater adaptability in energy balance regulation, while monogenic obesity models have impaired compensatory mechanisms due to genetic mutations. In this study, we assessed the metabolic impacts of mono, dual, and triple GLP-1 agonists on a monogenic (db/db) […]

Introduction and Objective: In Japan, FreeStyle Libre 2 (Libre 2)​ was approved as real-time continuous glucose monitoring (rtCGM) only when used smartphone application since its initial release, December 2023. Because early approval as rtCGM like Japan is uncommon, the efficacy of switching from intermittently scanned CGM (isCGM) to rtCGM with identical accuracy and specifications remains […]